Trial Condition(s):

Hypertension

COugh among hypertensive patients treated with telmisartan, who had to stop previoUs ACE-I treatment due to couGH in Poland (COUGH)

Bayer Identifier:

14881

ClinicalTrials.gov Identifier:

NCT01211171

EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

In the light of ONTARGET and TRANSCEND studies results, it would be interesting to investigate the real-life telmisartan treatment tolerability. It is well known and accepted that the Real-life setting is much more adequate to reflect the antihypertensive and safety properties of the drug in comparison to the organized and scheduled setting of the clinical trial. Because there are not much data on the cough in relation to telmisartan, therefore it would we worth to observe the cough frequency and general treatment tolerance in patients treated with telmisartan, who had to stop their previous ACE-I treatment due to cough.

Inclusion Criteria
- hypertension
 - age > 18
 - ACE-I related cough
Exclusion Criteria
- Current treatment with telmisartan
 - Cholestatic disorders and severe hepatic failure
 - Allergy to telmisartan 
 - Pregnancy and lactation period

Trial Summary

Enrollment Goal
2498
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Kinzal/Pritor (Telmisartan, BAY68-9291)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Locations
Locations

Investigative Site

Many Locations, Poland

Trial Design